Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that it has received marketing approval in Myanmar for its product Lumitin (conbercept) for the treatment of neovascular age-related macular degeneration (nAMD).
Lumitin, a fusion protein of VEGF receptor and human immunoglobulin Fc segment, is a modified version of Regeneron/Bayer’s Eylea (aflibercept). It was developed by Fang Jianmin, founder and CEO of RemeGen Ltd (HKG: 9995), and licensed to Kanghong Pharma. Initially approved in China in November 2013 for the treatment of wet AMD, Lumitin has since gained additional approvals: for visual impairment due to choroidal neovascularization secondary to pathologic myopia (pmCNV) in May 2017, for diabetic macular edema in May 2019, and for visual impairment caused by macular edema in retinal vein occlusion (RVO), including branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), in 2022. The product was included in China’s National Reimbursement Drug List (NRDL) in July 2017.- Flcube.com
